What Could Push LLY Stock Higher From Here?
While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.
Yet the sheer scale of the cardiometabolic franchise makes top-line growth the primary lever for the stock. The Mounjaro and Zepbound alone generated a combined $12.8 billion in the last quarter. This is the engine that must keep compounding for the upside case to work.
That’s the story. The cleanest way to interrogate it is to break the 3-year stock move in Eli Lilly (LLY) into the three things that can drive it: revenue compounding, net margin trajectory, and the multiple itself. Then look at which one is doing the heavy lifting under conservative assumptions.
The Three Levers Of Upside
Today’s price is paying for some combination of these three. Under our conservative calibration:
- Why Is NVDA Stock The Discount Option Among Its Peers?
- The Real Engine Driving Netflix Stock Is Its Earnings Power
- Tesla Stock’s Future Comes With A Hefty Price Tag
- 6 Red Days In A Row: Beam Therapeutics Stock Is Down 19%
- The Premium On Airbnb Keeps Growing. So Does The Case For Booking
- Why Abbott Stock Is Reimagining Its Future
- Revenue compounding at 30% annually. Top line moves from $72.2B to $158.7B. Standalone contribution to the price move: 120%.
- Net margin eases from 35% to 32%. Standalone contribution: -10%.
- P/E multiple compresses further from 40.9x to 36.4x as a slower forward growth rate no longer supports today’s multiple, even though it already sits below its 3-year average. Standalone contribution: -11%.
Multiplied through, the three combine to roughly 76% of upside over three years. Before we stress each one, here is the picture they are operating on top of:
| LLY | |
|---|---|
| Sector | Health Care |
| Industry | Pharmaceuticals |
| P/E Ratio | 40.9 |
| P/E Ratio 3Y Avg | 71.0 |
| LTM* Revenue Growth | 47% |
| 3Y Avg Revenue Growth | 38% |
| LTM* Net Margin | 35% |
| 3Y Peak Net Margin | 35% |
| 3Y Avg Net Margin | 23% |
*LTM: Last Twelve Months
What Happens To Upside If The Levers Change?
The base case lands at 76%. Soften revenue compounding by 200 basis points, so the top line grows at 28% instead of 30%, and the upside slides toward 68%. Let net margin give back to the 3-year average of 23%, below the 32% the base case holds, and it lands closer to 30%. The multiple is the most powerful lever in the other direction: hold it flat at today’s 40.9x rather than letting it compress as the base case assumes, and the upside actually climbs to 98%. That gap is what the multiple compression is costing the case. And stretching the horizon from 3 years to 5 lifts the upside to 197%, with the math compounding in the patient investor’s favor.
What Could Tilt The Levers Higher
The next wave of growth may come from converting an entirely new set of doctors and patients. The recent launch of the company’s oral GLP-1, Foundayo, has already attracted over 8,000 prescribers. Critically, a third of them had not previously been prescribed a drug in this class, signaling true market expansion.
What Could Break The Combination
The primary risk surfaced on the call is not demand, but price. Management explicitly guides for price to be a headwind in the low to mid-teens for the full year. This pressure is already visible in the latest results, where the U.S. price declined by 7%.
Which Lever Carries The Weight
Of the three levers, revenue compounding is doing the most. Margins and the multiple are supporting actors that can chip in or chip away, but the case lives or dies on the top line moving at roughly the projected pace. All of this sits on top of a cyclical asterisk: today’s LTM comes off a peak rather than a sustainable rate, so the projection itself starts at a level that may not persist through-cycle.
The company’s ability to attract new prescribers creates a tangible growth path, but the expected pricing headwinds will challenge that new volume.
Should You Invest In Eli Lilly?
For a different read on LLY, see our recent piece What Lilly’s Peer-Beating Numbers Cost You.
A careful 3-year case on a single name is still a concentrated bet, as historical volatility across past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book, partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.
If it is exposure to healthcare as a whole you want, rather than this one name, a healthcare ETF like XLV covers that single sector. Going broader than any one sector, to a quality-first mix across the whole market, is where the portfolio below comes in.
The Trefis High Quality (HQ) Portfolio combines analytical rigor with a forward-looking view across 30 stocks, with a consistent selection framework and a sizing and rebalancing discipline designed to deliver upside without the single-name risk you just read through here.
By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.